Focused On-demand Library for 2'-5'-oligoadenylate synthase 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P29728

UPID:

OAS2_HUMAN

Alternative names:

p69 OAS / p71 OAS

Alternative UPACC:

P29728; A8K9T1; Q6PJ33; Q86XX8

Background:

2'-5'-oligoadenylate synthase 2, known as p69 OAS/p71 OAS, plays a pivotal role in the innate antiviral response. It is activated by double-stranded RNA, leading to the synthesis of 2'-5'-oligoadenylates that activate RNASEL, resulting in viral RNA degradation and inhibition of viral replication. Beyond its antiviral function, it influences apoptosis, cell growth, differentiation, gene regulation, and may act as a lactation regulator.

Therapeutic significance:

Understanding the role of 2'-5'-oligoadenylate synthase 2 could open doors to potential therapeutic strategies.